BioArctic’s Board of Directors and management increase their shareholdings

Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that nine members of the company’s Board and management today have called for redemption of share options in accordance with the option agreement concluded with the principal owners of BioArctic AB.

Nine members who are part of BioArctic’s Board of Directors and management have today called for redemption of share options in accordance with the option agreement concluded with the principal owners of BioArctic AB. The option agreement runs until June 30, 2020.

The program comprises a total of 366,795 shares divided among twelve members of the BioArctic Board of Directors and management. Today, a total of 207,405 shares were acquired at the exercise price of SEK 26.67 per share, leaving a further 159,390 shares available for redemption.

After the transaction, the two founders’ and principal owners’ holdings amount to:

• Lars Lannfelt: ownership via Demban AB of 35.62 percent of the shares and 50.13
percent of the votes
• Pär Gellerfors: ownership via Ackelsta AB of 23.75 percent of the shares and 33.42 percent of the votes

“It is gratifying to see that the Board of Directors and management of BioArctic are committed and see the company´s future positively. Increased share ownership reinforces engagement,” says BioArctics chairman Wenche Rolfsen in a comment.

For more information, please contact:
Jan Mattsson, CFO, BioArctic AB
Telephone: +46 8 695 69 30
Mobile: +46 70 352 27 72
E-mail: jan.mattsson@bioarctic.se

This information was submitted for publication at 19:30 CET on May 9, 2019.

About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). www.bioarctic.com